Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » The Diagnostic Value of Circulating Cell-Free HPV DNA in ...

Om AU

The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Standard

The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. / Bønløkke, Sara; Stougaard, Magnus; Sorensen, Boe Sandahl et al.
I: Cells, Bind 11, Nr. 14, 2170, 07.2022.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Harvard

Bønløkke, S, Stougaard, M, Sorensen, BS, Booth, BB, Høgdall, E, Nyvang, GB, Lindegaard, JC, Blaakær, J, Bertelsen, J, Fuglsang, K, Strube, ML, Lenz, S & Steiniche, T 2022, 'The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients', Cells, bind 11, nr. 14, 2170. https://doi.org/10.3390/cells11142170

APA

Bønløkke, S., Stougaard, M., Sorensen, B. S., Booth, B. B., Høgdall, E., Nyvang, G. B., Lindegaard, J. C., Blaakær, J., Bertelsen, J., Fuglsang, K., Strube, M. L., Lenz, S., & Steiniche, T. (2022). The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. Cells, 11(14), artikel 2170. https://doi.org/10.3390/cells11142170

CBE

Bønløkke S, Stougaard M, Sorensen BS, Booth BB, Høgdall E, Nyvang GB, Lindegaard JC, Blaakær J, Bertelsen J, Fuglsang K, et al. 2022. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. Cells. 11(14):Article 2170. https://doi.org/10.3390/cells11142170

MLA

Bønløkke, Sara et al. "The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients". Cells. 2022. 11(14). https://doi.org/10.3390/cells11142170

Vancouver

Bønløkke S, Stougaard M, Sorensen BS, Booth BB, Høgdall E, Nyvang GB et al. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. Cells. 2022 jul.;11(14):2170. doi: 10.3390/cells11142170

Author

Bønløkke, Sara ; Stougaard, Magnus ; Sorensen, Boe Sandahl et al. / The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. I: Cells. 2022 ; Bind 11, Nr. 14.

Bibtex

@article{020dc478c4e948ea9f60fae2cadb7480,
title = "The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients",
abstract = "Circulating cell-free HPV DNA (ccfHPV DNA) may serve as a marker for cervical cancer. In this study, we used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in plasma from patients with HPV16- or HPV18-associated cervical cancer. Blood samples from 60 patients diagnosed with cervical cancer (FIGO IA1-IVA) at Aarhus or Odense University Hospital (June 2018 to March 2020) were collected prior to treatment, and patients were subdivided into an early stage (n = 30) and a late-stage subgroup (n = 30) according to disease stage. Furthermore, blood samples from eight women with HPV16- or 18-associated premalignant conditions (CIN3), and 15 healthy controls were collected. ddPCR was used to analyze plasma from all participants. ccfHPV DNA was detected in 19 late-stage patients (63.33%), 3 early stage patients (10.00%), and none of the CIN3 patients or controls. Quantitative evaluation showed significant correlations between ccfHPV DNA level and stage, tumor score, and tumor size. Thus, our results indicate that ccfHPV DNA may not be a useful marker for early detection of cervical cancer. However, for patients with advanced stage cervical cancer, ccfHPV DNA level represents a promising tool to establish tumor burden, making it useful for establishing treatment response and monitoring the disease.",
keywords = "ccfHPV DNA, cervical cancer, circulating cell-free DNA, circulating cell-free HPV DNA, circulating tumor DNA, ctDNA, ddPCR, digital droplet PCR, HPV, human papillomavirus",
author = "Sara B{\o}nl{\o}kke and Magnus Stougaard and Sorensen, {Boe Sandahl} and Booth, {Berit Bargum} and Estrid H{\o}gdall and Nyvang, {Gitte Bettina} and Lindegaard, {Jacob Christian} and Jan Blaak{\ae}r and Jesper Bertelsen and Katrine Fuglsang and Strube, {Mikael Lenz} and Suzan Lenz and Torben Steiniche",
note = "Funding Information: This research was funded by IMK Almene Fond, grant number 30-206-365; Civilingeni{\o}r Frode V. Nyegaard og hustrus fond, grant number 12-06-2018; Fabrikant Einar Willumsens Mindelegat, grant number 6000073; Folketingsmand J. Christensen og hustrus K. Christensens Fond til st{\o}tte af forskning i kr{\ae}ft- og AIDS-sygdomme, grant number 21012021; Grosserer A.V. Lykfeldts og Hustrus legat, grant number 27022021; Harboefonden, grant number 19181; Holms Mindelegat, grant number 20006-1902; Inge og J{\o}rgen Larsens mindelegat, grant number 105 37-05; Krista og Viggo Petersens Fond, grant number 6030/67; S{\o}ster og Verner Lipperts fond, grant number 13-12-2017; Vissingfonden, grant number 54622; and Aase og Ejnar Danielsens Fond, grant number 10-002130. Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
month = jul,
doi = "10.3390/cells11142170",
language = "English",
volume = "11",
journal = "Cells",
issn = "2073-4409",
publisher = "MDPI AG",
number = "14",

}

RIS

TY - JOUR

T1 - The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients

AU - Bønløkke, Sara

AU - Stougaard, Magnus

AU - Sorensen, Boe Sandahl

AU - Booth, Berit Bargum

AU - Høgdall, Estrid

AU - Nyvang, Gitte Bettina

AU - Lindegaard, Jacob Christian

AU - Blaakær, Jan

AU - Bertelsen, Jesper

AU - Fuglsang, Katrine

AU - Strube, Mikael Lenz

AU - Lenz, Suzan

AU - Steiniche, Torben

N1 - Funding Information: This research was funded by IMK Almene Fond, grant number 30-206-365; Civilingeniør Frode V. Nyegaard og hustrus fond, grant number 12-06-2018; Fabrikant Einar Willumsens Mindelegat, grant number 6000073; Folketingsmand J. Christensen og hustrus K. Christensens Fond til støtte af forskning i kræft- og AIDS-sygdomme, grant number 21012021; Grosserer A.V. Lykfeldts og Hustrus legat, grant number 27022021; Harboefonden, grant number 19181; Holms Mindelegat, grant number 20006-1902; Inge og Jørgen Larsens mindelegat, grant number 105 37-05; Krista og Viggo Petersens Fond, grant number 6030/67; Søster og Verner Lipperts fond, grant number 13-12-2017; Vissingfonden, grant number 54622; and Aase og Ejnar Danielsens Fond, grant number 10-002130. Publisher Copyright: © 2022 by the authors.

PY - 2022/7

Y1 - 2022/7

N2 - Circulating cell-free HPV DNA (ccfHPV DNA) may serve as a marker for cervical cancer. In this study, we used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in plasma from patients with HPV16- or HPV18-associated cervical cancer. Blood samples from 60 patients diagnosed with cervical cancer (FIGO IA1-IVA) at Aarhus or Odense University Hospital (June 2018 to March 2020) were collected prior to treatment, and patients were subdivided into an early stage (n = 30) and a late-stage subgroup (n = 30) according to disease stage. Furthermore, blood samples from eight women with HPV16- or 18-associated premalignant conditions (CIN3), and 15 healthy controls were collected. ddPCR was used to analyze plasma from all participants. ccfHPV DNA was detected in 19 late-stage patients (63.33%), 3 early stage patients (10.00%), and none of the CIN3 patients or controls. Quantitative evaluation showed significant correlations between ccfHPV DNA level and stage, tumor score, and tumor size. Thus, our results indicate that ccfHPV DNA may not be a useful marker for early detection of cervical cancer. However, for patients with advanced stage cervical cancer, ccfHPV DNA level represents a promising tool to establish tumor burden, making it useful for establishing treatment response and monitoring the disease.

AB - Circulating cell-free HPV DNA (ccfHPV DNA) may serve as a marker for cervical cancer. In this study, we used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in plasma from patients with HPV16- or HPV18-associated cervical cancer. Blood samples from 60 patients diagnosed with cervical cancer (FIGO IA1-IVA) at Aarhus or Odense University Hospital (June 2018 to March 2020) were collected prior to treatment, and patients were subdivided into an early stage (n = 30) and a late-stage subgroup (n = 30) according to disease stage. Furthermore, blood samples from eight women with HPV16- or 18-associated premalignant conditions (CIN3), and 15 healthy controls were collected. ddPCR was used to analyze plasma from all participants. ccfHPV DNA was detected in 19 late-stage patients (63.33%), 3 early stage patients (10.00%), and none of the CIN3 patients or controls. Quantitative evaluation showed significant correlations between ccfHPV DNA level and stage, tumor score, and tumor size. Thus, our results indicate that ccfHPV DNA may not be a useful marker for early detection of cervical cancer. However, for patients with advanced stage cervical cancer, ccfHPV DNA level represents a promising tool to establish tumor burden, making it useful for establishing treatment response and monitoring the disease.

KW - ccfHPV DNA

KW - cervical cancer

KW - circulating cell-free DNA

KW - circulating cell-free HPV DNA

KW - circulating tumor DNA

KW - ctDNA

KW - ddPCR

KW - digital droplet PCR

KW - HPV

KW - human papillomavirus

UR - http://www.scopus.com/inward/record.url?scp=85136248540&partnerID=8YFLogxK

U2 - 10.3390/cells11142170

DO - 10.3390/cells11142170

M3 - Journal article

C2 - 35883612

AN - SCOPUS:85136248540

VL - 11

JO - Cells

JF - Cells

SN - 2073-4409

IS - 14

M1 - 2170

ER -